🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma NCT06753747Phase 1, Phase 21 site📍 Chengdu West China Hospital · Tests: Palbociclib, Afatinib(30mg), Afatinib(40mg), Afatinib(RP2D) EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC NCT07617805Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT NCT07448727n/a1 site📍 Rome University of Rome Tor Vergata Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT07744126Phase 24 sites📍 Duarte📍 Newnan📍 Taichung AbbVie · Tests: Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. NCT07791745Phase 2, Phase 31 site📍 Shanghai Taizhou Mabtech Pharmaceutical Co.,Ltd · Tests: Enlituo® + Anyouping® + PBC, Placebo-Enlituo + Anyouping® + PBC TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma NCT07768189Phase 3111 sites📍 Huntsville📍 Tucson📍 Duarte Corbus Pharmaceuticals Inc. · Tests: CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China NCT04857164Phase 21 site📍 Beijing Yuankai Shi · Tests: Pembrolizumab combined with Chemotherapy Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN NCT07264075Phase 31 site📍 Le Havre Groupe Oncologie Radiotherapie Tete et Cou · Tests: Ivonescimab 10 mg/kg, Ligufalimab, Pembrolizumab (KEYTRUDA ®) A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants NCT07668154Phase 22 sites📍 Chengdu📍 Shanghai Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB571, Pembrolizumab, carboplatin, Cisplatin A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) NCT07408063Phase 21 site📍 Toronto University Health Network, Toronto · Tests: GSK5764227, Dostarlimab A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN NCT05751512Phase 31 site📍 Shanghai Lepu Biopharma Co., Ltd. · Tests: MRG003, Cetuximab injection, Methotrexate Injection Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC NCT06935188Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: Dalpicilib combined with cetuximab, cetuximab Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer NCT07481058Phase 21 site📍 Beijing Beijing Konruns Pharmaceutical Co., Ltd. · Tests: KC1036, Toripalimab, Paclitaxel, Cisplatin, KC1036 A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) NCT07136545Phase 1, Phase 23 sites📍 Taoyuan📍 Taipei📍 Taipei Taipei Veterans General Hospital, Taiwan · Tests: HCB101, Pembrolizumab A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer NCT07059221Phase 1, Phase 22 sites📍 Chongqing📍 Chengdu Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A2102, Adebrelimab, Cetuximab, SHR-9839(sc), Carboplatin / Cisplatin Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors NCT07081984Phase 11 site📍 Shanghai Therorna · Tests: therapeutic tumor vaccine A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC NCT07807163Phase 27 sites📍 Fort Myers📍 Orlando📍 St. Petersburg Bicara Therapeutics · Tests: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy NCT05283226Phase 213 sites📍 Fullerton📍 Los Angeles📍 Boca Raton NATCO Pharma Ltd. · Tests: NRC-2694-A, Paclitaxel A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06469008Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B16D1 Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC NCT05047094NA3 sites📍 Jerusalem📍 Ramat Gan📍 Tel Aviv Alpha Tau Medical LTD. · Tests: Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembrolizumab Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N NCT06640725Phase 21 site📍 Vandœuvre-lès-Nancy Groupe Oncologie Radiotherapie Tete et Cou · Tests: Avelumab administration at 10mg/kg, Cetuximab (Erbitux) Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies NCT06061705NA3 sites📍 Paris📍 Paris📍 Paris Fondation Hôpital Saint-Joseph · Tests: Tumor Biopsy Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer NCT07501650Phase 11 site📍 Philadelphia Thomas Jefferson University · Tests: Pembrolizumab, Definity, Ultrasound-Induced Microbubble Cavitation Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma NCT06211335Phase 12 sites📍 Sacramento📍 Aurora University of California, Davis · Tests: Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456Phase 2, Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Tislelizumab, 5-Fluorouracil, Cisplatin, Paclitaxel Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites📍 Orlando📍 Boston📍 Oklahoma City Sutro Biopharma, Inc. · Tests: STRO-006, Pembrolizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy